An observational study in Kidney Disease, Chronic, Peritoneal Dialysis and Diabetes Mellitus Type 2, sponsored by Coordinación de Investigación en Salud, Mexico. Recruiting at 2 sites in Mexico. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Coordinación de Investigación en Salud, Mexico · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Renal Insufficiency, Chronic with a site in Mexico — 19 open to participants now, 31 under way, 14 of them phase 3. Renal Insufficiency, Chronic · Mexico.
Among the 83 studies in Renal Insufficiency, Chronic with a site in Mexico, this one is one of 9 that started in 2024, is one of 6 observational ones, reaches primary completion later than 14 of the 30 other live ones, and was the 57th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →19 of the 83 studies in Renal Insufficiency, Chronic with a site in Mexico are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Mexico, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Mexico, United States, Argentina and 34 more countries
Ages 18+
Universidad Autonoma de Nuevo Leon · Sites in Mexico
Ages 18+
Centenario Hospital Miguel Hidalgo · Sites in Mexico
Ages 14–18
Eli Lilly and Company · Sites in Mexico, Argentina, Australia and 35 more countries
Ages 50+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 46 · Phase 4 3
First in 2003; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is below the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 341 across the 77 interventional studies, 2,807 across the 6 observational. Of the 47 that completed or were terminated, 33 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 83 have an industry lead sponsor. The 10 most frequent:
Coordinación de Investigación en Salud, Mexico is the lead sponsor of 98 studies on the registry; 16 are open to participants now.
Coordinación de Investigación en Salud, Mexico has 4 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
10 of the studies in Renal Insufficiency, Chronic with a site in Mexico that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07678203Hospital Civil Juan I. MenchacaDapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis | 2027-01-28 |
Add all 10 to your calendar (.ics) → With an account.
Among the 83 studies in Renal Insufficiency, Chronic with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Patients with chronic kidney disease (CKD) caused by diabetes mellitus (DM) experience metabolic alterations characterized by elevated blood glucose levels and associated cardiovascular complications, which increase morbidity and mortality. Therefore, adequate metabolic control is necessary to reduce the incidence of these complications. This task is challenging without icodextrin because insulin adjustment is complicated by the additional glucose supplied through dialysis bags and absorbed through the peritoneum.
Under this premise, continuous glucose monitoring is important for assessing patients' metabolic status. This approach will provide clinically relevant data to improve care, minimize healthcare system expenses, and support decision-making regarding adjustments to dialysis treatment.
Objective: To use continuous glucose monitoring to determine whether the type, dose, route of administration, and timing of insulin application are associated with glucose patterns identified through continuous glucose monitoring, including the magnitude and duration of periods of hyperglycemia and hypoglycemia during 24-hour periods of interstitial glucose monitoring.
Material and Methods: This is a cross-sectional, non-interventional study involving adult patients with type 2 diabetes mellitus receiving automated peritoneal dialysis who exhibit high or high-average peritoneal transport characteristics.
The inclusion criteria are patients older than 40 years, of any sex, diagnosed with diabetic nephropathy, who are insulin-dependent for metabolic control and have received peritoneal dialysis treatment for at least three months. The study will continuously evaluate patients' glycemic control, with automatic scanning and data recording every six hours during automated peritoneal dialysis infusion. According to the sample size calculation, 110 patients are required.
The Guardian 3 sensor will be placed subcutaneously in the upper posterior region of the patient's non-dominant arm using the One-press serter. This is a minimally invasive procedure that does not require surgical protocols. The sensor will be connected to the Guardian Connect transmitter for continuous communication with the Guardian Connect application.
The sensor has an approximate lifespan of seven days, corresponding to the duration of the enzymatic reaction that allows adequate measurement. Data will be transmitted every five minutes, 24 hours a day, for seven consecutive days. At the end of this period, participants will be scheduled for placement of a second sensor to complete 14 days of follow-up.
On day seven, participants will undergo removal of the first sensor and placement of a new sensor to complete the 14-day follow-up period. On day 14, the total 24-hour peritoneal dialysis drainage volume will be collected to measure glucose, urea, and creatinine concentrations. Peritoneal glucose absorption, the dialysate-to-plasma creatinine ratio (D/P creatinine), and Kt/V will be calculated. Dietary information will be collected to calculate caloric intake and meal timing. This information, together with subcutaneous insulin administration, will be recorded in the Guardian Connect application.
Statistical Analysis: The databases will be audited monthly through random sampling of blocks comprising 5% of their content. Semiannual reports will be prepared to monitor the records collected and the outcomes obtained up to each reporting date. These reports will contain basic descriptive information, including measures of central tendency and dispersion, according to the characteristics of the variables.
Patients will be classified according to the percentage of time that glucose measurements remain within the predefined range of 70-180 mg/dL. Patients who spend at least 70% of the time within this range will be classified as having "Adequate" glycemic control, whereas those who do not reach this target will be classified as having "Not Adequate" glycemic control.
Results will be reported using measures of central tendency and dispersion appropriate to the characteristics of the variables. Depending on the type of variable, the chi-square test, Student's t-test, or Mann-Whitney U test will be used to detect differences between the adequate and inadequate glycemic control groups.
Logistic regression analysis will be used to identify variables significantly associated with glycemic control within the recommended ranges, as assessed by continuous glucose monitoring. In the first stage, each independent variable will be analyzed separately. In the second stage, multivariable analysis will be performed, considering insulin type, route of administration, dose, and administration schedules. Potential confounding variables, including obesity, treatment adherence, diet, and physical activity prescribed by the treating physician, will also be included.
Background: Patients with chronic kidney disease (CKD) caused by diabetes mellitus (DM) experience metabolic alterations characterized by elevated blood glucose levels and associated cardiovascular complications, which increase morbidity and mortality. Therefore, adequate metabolic control is necessary to reduce the incidence of these complications. This task is challenging without icodextrin because insulin adjustment is complicated by the additional glucose supplied through dialysis bags and absorbed through the peritoneum.
Under this premise, continuous glucose monitoring is important for assessing patients' metabolic status. This approach will provide clinically relevant data to improve care, minimize healthcare system expenses, and support decision-making regarding adjustments to dialysis treatment.
Objective: To use continuous glucose monitoring to determine whether the type, dose, route of administration, and timing of insulin application are associated with glucose patterns identified through continuous glucose monitoring, including the magnitude and duration of periods of hyperglycemia and hypoglycemia during 24-hour periods of interstitial glucose monitoring.
Material and Methods: This is a cross-sectional, non-interventional study involving adult patients with type 2 diabetes mellitus receiving automated peritoneal dialysis who exhibit high or high-average peritoneal transport characteristics.
The inclusion criteria are patients older than 40 years, of any sex, diagnosed with diabetic nephropathy, who are insulin-dependent for metabolic control and have received peritoneal dialysis treatment for at least three months. The study will continuously evaluate patients' glycemic control, with automatic scanning and data recording every six hours during automated peritoneal dialysis infusion. According to the sample size calculation, 110 patients are required.
The Guardian 3 sensor will be placed subcutaneously in the upper posterior region of the patient's non-dominant arm using the One-press serter. This is a minimally invasive procedure that does not require surgical protocols. The sensor will be connected to the Guardian Connect transmitter for continuous communication with the Guardian Connect application.
The sensor has an approximate lifespan of seven days, corresponding to the duration of the enzymatic reaction that allows adequate measurement. Data will be transmitted every five minutes, 24 hours a day, for seven consecutive days. At the end of this period, participants will be scheduled for placement of a second sensor to complete 14 days of follow-up.
On day seven, participants will undergo removal of the first sensor and placement of a new sensor to complete the 14-day follow-up period. On day 14, the total 24-hour peritoneal dialysis drainage volume will be collected to measure glucose, urea, and creatinine concentrations. Peritoneal glucose absorption, the dialysate-to-plasma creatinine ratio (D/P creatinine), and Kt/V will be calculated. Dietary information will be collected to calculate caloric intake and meal timing. This information, together with subcutaneous insulin administration, will be recorded in the Guardian Connect application.
Statistical Analysis: The databases will be audited monthly through random sampling of blocks comprising 5% of their content. Semiannual reports will be prepared to monitor the records collected and the outcomes obtained up to each reporting date. These reports will contain basic descriptive information, including measures of central tendency and dispersion, according to the characteristics of the variables.
Patients will be classified according to the percentage of time that glucose measurements remain within the predefined range of 70-180 mg/dL. Patients who spend at least 70% of the time within this range will be classified as having "Adequate" glycemic control, whereas those who do not reach this target will be classified as having "Not Adequate" glycemic control.
Results will be reported using measures of central tendency and dispersion appropriate to the characteristics of the variables. Depending on the type of variable, the chi-square test, Student's t-test, or Mann-Whitney U test will be used to detect differences between the adequate and inadequate glycemic control groups.
Logistic regression analysis will be used to identify variables significantly associated with glycemic control within the recommended ranges, as assessed by continuous glucose monitoring. In the first stage, each independent variable will be analyzed separately. In the second stage, multivariable analysis will be performed, considering insulin type, route of administration, dose, and administration schedules. Potential confounding variables, including obesity, treatment adherence, diet, and physical activity prescribed by the treating physician, will also be included.
Detailed Description JUSTIFICATION The high prevalence of patients with end-stage chronic kidney disease (CKD) treated with peritoneal dialysis (PD) and the predominance of diabetes mellitus (DM) as a cause of CKD make it necessary to establish documented guidelines for metabolic control in patients with DM receiving PD.
These guidelines should consider insulin dosage in relation to glucose intake from food and glucose absorption through the peritoneum. They should also consider meal schedules, infusion schedules for PD solutions with higher glucose concentrations, and the route of insulin administration, since the intraperitoneal route requires up to twice the dose administered subcutaneously.
To develop these guidelines, monitoring metabolic control using conventional tools, such as blood glucose measurements with a portable glucometer or glycated hemoglobin, is insufficient because these methods do not allow identification of the times of day when insulin should be administered to optimize its use. Continuous glucose monitoring is the only practical tool available for this purpose.
Recent reports identify CKD as the third chronic degenerative disease with the greatest financial impact on the Mexican Social Security Institute (IMSS). Together with diabetes mellitus and hypertension, CKD accounts for a substantial proportion of healthcare expenditure for patients with chronic diseases. Moreover, patients with DM represent more than half of those enrolled in dialysis programs.
In this context, metabolic control and fluid balance in patients with DM receiving PD represent both clinical and economic challenges.
RESEARCH QUESTION Is continuous glucose monitoring an effective tool for detecting the effects of insulin type, dose, route of administration, and timing on metabolic control in patients with diabetes receiving peritoneal dialysis? OBJECTIVES
General Objective:
To use continuous glucose monitoring to determine whether insulin type, dose, route of administration, and timing are associated with glucose patterns identified through continuous glucose monitoring, including the magnitude and duration of periods of hyperglycemia and hypoglycemia during 24-hour periods of interstitial glucose monitoring.
Specific Objectives:
MATERIALS AND METHODS
Design:
Cross-sectional, non-interventional study.
Population:
Adult patients with type 2 diabetes mellitus (DM2) and end-stage CKD receiving peritoneal dialysis.
Inclusion Criteria: Patients older than 40 years, of any sex, diagnosed with diabetic nephropathy, who are exclusively insulin-dependent for metabolic control and have received PD treatment for at least three months.
Non-Inclusion Criteria: Patients with positive serology for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus; acute complications; hospitalization for cardiovascular, metabolic, or infectious conditions during the month preceding study enrollment; cancer; pregnancy; or allergy.
OUTCOMES
Primary:
Average glucose concentration detected during 24-hour periods. Magnitude and duration of periods of hypoglycemia (\<70 mg/dL) and hyperglycemia (>180 mg/dL) recorded during 24-hour periods.
Secondary:
Necessary adjustments in insulin dosage during the monitoring period. PROCEDURES A member of the research team will invite patients who meet the eligibility criteria, as identified in PD consultation records, to participate in the study. Eligible patients will receive information about the study objectives and procedures.
For patients who agree to participate and sign the informed consent form, the initial interview will collect demographic information (sex, age, marital status, educational level, economic activity, and income), clinical information (underlying disease, disease duration, previous hospitalizations, and comorbidities), and laboratory information (complete blood count, basic biochemical parameters, inflammatory markers, mineral metabolism, nutritional parameters, and cardiovascular parameters) available in their medical records.
Information will be collected by nursing staff trained in clinical research procedures (monitors). The data collected will correspond to established dialysis adequacy criteria and are specified in the attached forms.
Participants will be scheduled for blood sample collection for biochemical analysis, including glucose, urea, creatinine, total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, glycated hemoglobin, and C-reactive protein.
Participants will receive training in the use of the glucose monitor, which will be placed on the non-dominant arm. Once the monitor has been calibrated, participants will undergo monitoring for seven days. The first sensor will then be removed and replaced with a second sensor, completing a total follow-up period of 14 days.
The recorded data will be collected by the investigators and documented in forms designed for this purpose.
Patient training will consist of face-to-face theoretical and practical instruction. Proper performance of calibration procedures, glucose measurement consultation, and understanding of warning signals will be verified to ensure safe use of the monitoring device.
If glucose concentrations above 250 mg/dL are recorded at any time or persist for more than seven hours (30%) per day, participants will be referred for a detailed evaluation by their treating physician, who will have been previously informed of the inadequate metabolic control.
LABORATORY All biochemical and laboratory tests will be used for routine monitoring of patients receiving PD and will be performed at the affiliated hospital using standard automated techniques.
CONTINUOUS GLUCOSE MONITORING Guardian 3 sensor, Guardian Connect Transmitter Kit, and Guardian Connect System, consisting of the Guardian Connect transmitter, One-Press serter, Guardian Connect smartphone application (App), and standard printing equipment.
The sensor will be connected to the Guardian Connect transmitter for continuous communication with the Guardian Connect application. A smartphone is required for this purpose. If participants do not have a smartphone, one will be provided to enable appropriate follow-up.
After proper functioning has been verified through calibration supported by a glucometer and capillary blood glucose test strips, data will be transmitted every five minutes, 24 hours a day, for seven consecutive days. This period corresponds to the duration of the enzymatic reaction that allows adequate measurement.
At the end of the seven-day period, participants will be scheduled for placement of a second sensor to complete the 14-day follow-up period.
The information provided by the Guardian Connect system can be downloaded in Excel format and analyzed by the clinician through the CareLink website. The clinician will analyze trends, glucose concentration patterns, and major alerts indicating values outside the established range.
On day seven, participants will be scheduled for sensor removal, and the total 24-hour PD drainage volume will be collected for glucose, urea, and creatinine measurements. Peritoneal glucose absorption, the dialysate-to-plasma creatinine ratio (D/P creatinine), and Kt/V will also be calculated.
Dietary information will be obtained to calculate caloric intake and meal timing. Subcutaneous insulin administration will be recorded in the Guardian Connect application.
STATISTICAL PLAN The databases will be audited monthly through random sampling of blocks comprising 5% of their content.
Semiannual reports will be prepared to monitor the records collected and the outcomes obtained up to each reporting date. These reports will contain basic descriptive information, including measures of central tendency and dispersion, according to the characteristics of the variables.
Patients will be classified according to the percentage of time that glucose measurements remain within the predefined range of 70-180 mg/dL (24). Patients who spend at least 70% of the time within this range will be classified as having "Adequate" glycemic control, whereas those who do not reach this target will be classified as having "Not Adequate" glycemic control.
Results will be reported using measures of central tendency and dispersion appropriate to the characteristics of the variables.
Depending on the type of variable, the chi-square test, Student's t-test, or Mann-Whitney U test will be used to identify differences between the adequate and inadequate glycemic control groups.
Logistic regression analysis will be used to identify variables significantly associated with glycemic control within the recommended ranges, as assessed by continuous glucose monitoring.
In the first stage, each independent variable will be analyzed separately. In the second stage, multivariable analysis will be performed, considering insulin type, route of administration, dose, and administration schedules.
Potential confounding variables, including obesity, treatment adherence, diet, and physical activity prescribed by the treating physician, will also be included.
According to the protocol, the independent variables considered will be daily glucose absorption, insulin dose, administration timing in relation to food intake and the PD solutions used, and route of administration.
All analyses will be performed using SPSS version 24. Statistical significance will be established at p\<0.05.
SAMPLE SIZE The following assumptions were used to calculate the sample size:Statistical test: Logistic regression.
Dependent variable: Time spent with interstitial glucose concentrations within the target range, dichotomized as "Adequate" or "Not Adequate."Dominant covariate: Route of insulin administration, dichotomized as "Subcutaneous" or "Intraperitoneal."This variable is considered the most important covariate because it has been associated with better glycemic control in studies using individual blood glucose measurements obtained with a portable glucometer and glycated hemoglobin as indicators of metabolic control.α: 0.05.β: 0.9.OR: Risk of time outside the target range >85% (Intraperitoneal/Subcutaneous): 0.46/0.30.
Sample size: N = 110. ETHICAL ASPECTS The research will be conducted in accordance with the ethical principles and guidelines established in the Official Mexican Standard NOM-028-SSA2-1999, the General Health Law regarding research involving human participants, Articles 96 and 100 of Title V, and Technical Standard No. 313.
These regulations establish protections for participants' rights, dignity, well-being, and anonymity.
The following guidelines will be observed:An informed consent form is included and will be presented to participants by associated investigators duly accredited by the authorities of the participating medical units.
According to Article 21 of the Regulations of the General Health Law on Health Research (1984), informed consent requires that research participants or, when applicable, their legal representatives receive a clear and complete explanation that allows them to understand the relevant aspects of the study.
This research is considered minimal risk because it involves standard procedures used in routine physical examinations, diagnoses, or treatments. It also involves a device supported by published evidence that can provide additional parameters for metabolic control in patients with diabetes.
The use of this device does not involve venous bleeding or direct insulin administration, as the sensor is placed intradermally. The device may generate alerts that participants will be trained to recognize and manage appropriately.
According to clinical experience in the management of patients receiving PD, the observed glucose variations are within ranges that do not represent a risk to participants but may allow optimization of insulin administration.
If glucose concentrations above 250 mg/dL are recorded at any time or persist for more than seven hours (30%) per day, participants will be referred for a detailed evaluation by their treating physician, who will have been previously informed of the inadequate metabolic control.
The risk-benefit balance is considered favorable because the potential value of the information obtained is relevant and the study involves minimal risk.
None of the participating investigators has a conflict of interest regarding the use of the Guardian Connect device.
Samples will be handled by experienced personnel and prepared at each center, since only glycated hemoglobin measurements and clinical laboratory tests will be performed before participants' monthly consultations.
The research team acknowledges the General Health Law regarding research, as well as the applicable regulations and biosafety manuals. The following considerations will be observed:Installation of the Guardian Connect sensor requires trained personnel. The Latam Medtronic Academy provides training to minimize risks and ensure appropriate handling of installation materials.
No samples will be processed in a central laboratory because samples will be processed at each participating center to avoid transferring serum or plasma between centers.
The use of appropriate personal protective equipment is strongly recommended when installing sensors in patients receiving dialysis.
RESOURCES, FINANCING, AND FEASIBILITY The research team comprises a nephrologist with clinical experience in hospital-based patient care, a researcher specializing in nephrology, and two nurses. Electronic data collection will also be performed by trained personnel.
Additional anticipated costs are associated with the electronic devices required for continuous glucose monitoring, for which resources will be necessary.
The research group has demonstrated experience through various publications in the field of nephrology.
The criteria were revised on the registry on Oct 21, 2026. See what changed
Adults with type 2 diabetes mellitus and diabetic nephropathy receiving peritoneal dialysis for at least three months and requiring insulin for glycemic control. Trained research staff will identify eligible patients from peritoneal dialysis clinic records and invite them to participate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Average glucose concentration detected in 24-hour periods.
Amount of time that blood glucose is within the target range during and after dialysis fluid infusion. Measurement of time in which blood glucose levels are within the lower range of 70 mg/dL and an upper range of 180 mg/dL during and after the infusion of dialysis fluid.
Time frame: 14 days of follow-up
Magnitude and duration of periods1s of hiccups (<70 mg/dl) and hyperglycemia (>180 mg/dl) recorded in 24-hour periods.
Presence of hypoglycemia (glucose concentration less than 70 mg/dL) or hyperglycemia (glucose concentration greater than 180 mg/dL).
Time frame: 14 days of follow-up
Plan to share: Undecided
Started Jun 2024 (actual). Primary completion is estimated for Mar 2027, 33 months after the start.
Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 33 months is below that.
Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Nov 2023 → Jun 2024, primary completion Jun 2024 → Mar 2027 and completion Nov 2024 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Coordinación de Investigación en Salud, Mexico